Annals of the New York Academy of Sciences
-
Ann. N. Y. Acad. Sci. · Oct 1999
Study on the distribution pattern of skin temperature in normal Chinese and detection of the depth of early burn wound by infrared thermography.
Conduct basic research of the distribution pattern of skin temperature and estimate the wound depth in normal Chinese in the early stage of burn injury by using technical thermography. ⋯ The depth of early burn wound can be detected by using infrared thermography, which is an objective, fast, non-touching, and noninvasive method.
-
A total of 211 patients were admitted at the UP-PGH Burn Unit in 1995. Sixty-eight (32.2%) patients suffered burn injuries secondary to electrical injury. In the period from July to December 1995, a total of 28 patients were admitted because of burns caused by electricity. ⋯ A total of 22 operations were performed on 28 patients, including 7 extremity amputations, which makes an amputation rate of 25%. There were 5 deaths secondary to overwhelming wound sepsis, making an overall mortality rate of 21.7% and an operative mortality rate of 22.7%. The average length of hospital stay was 17.2 days.
-
Ann. N. Y. Acad. Sci. · Jun 1999
The novel Trk receptor tyrosine kinase inhibitor CEP-701 (KT-5555) exhibits antitumor efficacy against human pancreatic carcinoma (Panc1) xenograft growth and in vivo invasiveness.
The survival rate for patients with pancreatic ductal adenocarcinoma (PDAC) is among the poorest for all cancers. The factors that contribute to this poor prognosis are lack of effective early detection, high rate of metastases and a generally refractory response to available treatment modalities. The most commonly used treatment methods--chemotherapy and radiation therapy--are mainly used for symptom palliation, with surgery being the only "curative" treatment option. ⋯ A T/C value of 25% was observed for CEP-701-treated s.c. xenografts. In addition, CEP-701 administration inhibited tumor cell invasion in the s.c. tracheal xenograft model of in vivo invasiveness. Taken together, these data suggest that further studies are warranted to evaluate CEP-701 as a potential therapeutic agent in the treatment of PDAC.